Skip to Main Content
Study population icon

Study Population

View the characteristics of the SJLIFE cohort relative to the CCSS cohort. The table was last updated October 31, 2022.


Characteristics Breakdown SJLIFE Cohort (n=9366)
Dx 1962-2012
CCSS Cohort (n=25,665)
Dx 1970-99
Sex Female 45.3% 46.5%
Male 54.7% 53.5%
Race Ethnicity White not Hispanic 76.8% 79.4%
Black not Hispanic 16.9% 6.2%
American Indian/Alaska Native 0.1% <1.0%
Asian Pacific Islander 0.5% 0.5%
Hispanic 4.0% 7.8%
Other 1.5% 3.3%
Unknown 0.2% 1.1%
Primary Diagnosis Leukemia 32.1% 30.7%
Lymphoma 15.3% 20.3%
CNS tumor 18.0% 17.5%
Embryonal tumors 17.3% 16.5%
Bone and Soft Tissue Sarcoma 11.9% 15.0%
Carcinoma 0.8% 0.0%
Other 4.6% 0.0%

Geographic distribution of SJLIFE participants

The SJLIFE cohort is geographically diverse with the largest proportion of participants from the mid-South region of the United States.

Map of geographic distribution of SJLIFE participants

Recruitment status of SJLIFE

As of April 30, 2020, for survivors where attempts to contact have been initiated, 80.4% (6006/7467) have been successfully enrolled and 87.8% have enrolled or have confirmed their interest in participating. Of all eligible survivors who are alive, 73.5% (6006/8173) have thus far been enrolled and 80.2% have enrolled or confirmed their interest in participating.

Pie chart of distribution of pediatric cancers

Cohort Recruitment Summary

Survivor participants who have completed their baseline clinical assessment are invited to return for subsequent systematic evaluations at a minimum of every 5 years. As of April 30, 2020: 53% (2776/5229) of survivors who had completed a baseline clinical assessment have returned for one or more subsequent follow-up assessments.

Distribution of Pediatric Cancers

SJLIFE includes all pediatric hematological and solid malignancies.

Pie chart of distribution of pediatric cancers

Monthly New Survivor and Control Enrollments

SJLIFE UU01 Cohort Expansion bar graphs

Related Information